BRISTOL-MYERS SQUIBB COMPANY (BMY) Spending and interest coverage
- R&D / revenue · 12 months: Value 21.80%; Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 1.12%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | 21.80% | Research and development expense / revenue. Period ending 2026-06-30. $10.72B ÷ $49.19B × 100 ≈ 21.80% |
| Stock-based compensation / revenue · 12 months | 1.12% | Share-based compensation / revenue. Period ending 2026-06-30. $553.00M ÷ $49.19B × 100 ≈ 1.12% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 10.72B USD | Research and Development Expense |
| Revenue | 49.19B USD | |
| Stock-based compensation | 553.00M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | (m) | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $10.72B | $49.19B | $553.00M | (m) | (m) | 21.80% | 1.12% | (m) | (m) |
| 2026-03-31 | $10.34B | $48.48B | $555.00M | (m) | (m) | 21.33% | 1.14% | (m) | (m) |
| 2025-12-31 | $9.95B | $48.19B | $553.00M | (m) | (m) | 20.65% | 1.15% | (m) | (m) |
| 2025-09-30 | $10.56B | $48.03B | $540.00M | (m) | (m) | 21.98% | 1.12% | (m) | (m) |
| 2025-06-30 | $10.40B | $47.70B | $530.00M | (m) | (m) | 21.81% | 1.11% | (m) | (m) |
| 2025-03-31 | $10.72B | $47.64B | $518.00M | (m) | (m) | 22.51% | 1.09% | (m) | (m) |
| 2024-12-31 | $11.16B | $48.30B | $507.00M | (m) | (m) | 23.10% | 1.05% | (m) | (m) |
| 2024-09-30 | $10.45B | $47.44B | $514.00M | (m) | (m) | 22.02% | 1.08% | (m) | (m) |
| 2024-06-30 | $10.31B | $46.51B | $517.00M | (m) | (m) | 22.18% | 1.11% | (m) | (m) |
| 2024-03-31 | $9.67B | $45.53B | $529.00M | (m) | $1.30B | 21.24% | 1.16% | (m) | Reported |
| 2023-12-31 | $9.30B | $45.01B | $518.00M | (m) | $1.17B | 20.66% | 1.15% | (m) | Reported |
| 2023-09-30 | $9.33B | $44.94B | $510.00M | (m) | $1.14B | 20.77% | 1.13% | (m) | Reported |
| 2023-06-30 | $9.51B | $45.19B | $493.00M | (m) | $1.16B | 21.04% | 1.09% | (m) | Reported |
| 2023-03-31 | $9.57B | $45.85B | $472.00M | (m) | $1.19B | 20.87% | 1.03% | (m) | Reported |
| 2022-12-31 | $9.51B | $46.16B | $457.00M | (m) | $1.23B | 20.60% | 0.99% | (m) | Reported |
| 2022-09-30 | $10.68B | $46.74B | $471.00M | (m) | $1.26B | 22.84% | 1.01% | (m) | Reported |
| 2022-06-30 | $11.24B | $47.14B | $498.00M | (m) | $1.29B | 23.84% | 1.06% | (m) | Reported |
| 2022-03-31 | $11.39B | $46.96B | $539.00M | (m) | $1.31B | 24.27% | 1.15% | (m) | Reported |
| 2021-12-31 | $11.35B | $46.38B | $583.00M | (m) | $1.33B | 24.48% | 1.26% | (m) | Reported |
| 2021-09-30 | $12.50B | $45.47B | $621.00M | (m) | $1.37B | 27.49% | 1.37% | (m) | Reported |
| 2021-06-30 | $11.74B | $44.38B | $664.00M | (m) | $1.38B | 26.46% | 1.50% | (m) | Reported |
| 2021-03-31 | $11.00B | $42.81B | $720.00M | (m) | $1.41B | 25.69% | 1.68% | (m) | Reported |
| 2020-12-31 | $11.14B | $42.52B | $779.00M | (m) | $1.42B | 26.21% | 1.83% | (m) | Reported |
| 2020-09-30 | $9.49B | $39.40B | $892.00M | (m) | $1.34B | 24.09% | 2.26% | (m) | Reported |
| 2020-06-30 | $8.37B | $34.86B | $763.00M | (m) | $1.21B | 24.01% | 2.19% | (m) | Reported |
| 2020-03-31 | $7.17B | $31.01B | $598.00M | (m) | $973.00M | 23.13% | 1.93% | (m) | Reported |
| 2019-12-31 | $6.15B | $26.14B | $441.00M | (m) | $656.00M | 23.52% | 1.69% | (m) | Reported |
| 2019-09-30 | $5.44B | $24.17B | $210.00M | (m) | $425.00M | 22.51% | 0.87% | (m) | Reported |
| 2019-06-30 | $5.34B | $23.86B | $216.00M | (m) | $260.00M | 22.38% | 0.91% | (m) | Reported |
| 2019-03-31 | $6.45B | $23.29B | $219.00M | (m) | $182.00M | 27.68% | 0.94% | (m) | Reported |
| 2018-12-31 | $6.34B | $22.56B | $221.00M | (m) | $183.00M | 28.12% | 0.98% | (m) | Reported |
| 2018-09-30 | $6.83B | $22.04B | $218.00M | (m) | $186.00M | 31.01% | 0.99% | (m) | Reported |
| 2018-06-30 | $7.11B | $21.60B | $206.00M | (m) | $190.00M | 32.94% | 0.95% | (m) | Reported |
| 2018-03-31 | $6.36B | $21.04B | $209.00M | (m) | $197.00M | 30.22% | 0.99% | (m) | Reported |
| 2017-12-31 | $6.41B | $20.78B | $199.00M | (m) | $196.00M | 30.86% | 0.96% | (m) | Reported |
| 2017-09-30 | $5.89B | $20.57B | $205.00M | (m) | $185.00M | 28.63% | 1.00% | (m) | Reported |
| 2017-06-30 | $5.49B | $20.24B | $203.00M | (m) | $179.00M | 27.10% | 1.00% | (m) | Reported |
| 2017-03-31 | $5.09B | $19.96B | $203.00M | (m) | $169.00M | 25.50% | 1.02% | (m) | Reported |
| 2016-12-31 | $4.94B | $19.43B | $205.00M | (m) | $167.00M | 25.43% | 1.06% | (m) | Reported |
| 2016-09-30 | $5.46B | $18.47B | $208.00M | (m) | $170.00M | 29.54% | 1.13% | (m) | Reported |
| 2016-06-30 | $5.45B | $17.62B | $223.00M | (m) | $169.00M | 30.93% | 1.27% | (m) | Reported |
| 2016-03-31 | $6.04B | $16.91B | $228.00M | (m) | $176.00M | 35.72% | 1.35% | (m) | Reported |
| 2015-12-31 | $5.92B | $16.56B | $235.00M | (m) | $184.00M | 35.75% | 1.42% | (m) | Reported |
| 2015-09-30 | $5.19B | $16.53B | $242.00M | (m) | $194.00M | 31.41% | 1.46% | (m) | Reported |
| 2015-06-30 | $5.04B | $16.38B | $227.00M | (m) | $203.00M | 30.79% | 1.39% | (m) | Reported |
| 2015-03-31 | $4.60B | $16.11B | $218.00M | (m) | $200.00M | 28.58% | 1.35% | (m) | Reported |
| 2014-12-31 | $4.53B | $15.88B | $213.00M | (m) | $203.00M | 28.55% | 1.34% | (m) | Reported |
| 2014-09-30 | $4.30B | $16.06B | $198.00M | (m) | $203.00M | 26.78% | 1.23% | (m) | Reported |
| 2014-06-30 | $4.21B | $16.21B | $195.00M | (m) | $199.00M | 25.99% | 1.20% | (m) | Reported |
| 2014-03-31 | $3.75B | $16.36B | $191.00M | (m) | $203.00M | 22.90% | 1.17% | (m) | Reported |
| 2013-12-31 | $3.73B | $16.39B | $191.00M | (m) | $199.00M | 22.77% | 1.17% | (m) | Reported |
| 2013-09-30 | $3.86B | $16.14B | $186.00M | (m) | $197.00M | 23.90% | 1.15% | (m) | Reported |
| 2013-06-30 | $3.91B | $15.81B | $167.00M | (m) | $199.00M | 24.76% | 1.06% | (m) | Reported |
| 2013-03-31 | $3.92B | $16.20B | $161.00M | (m) | $190.00M | 24.23% | 0.99% | (m) | Reported |
| 2012-12-31 | $3.90B | $17.62B | $154.00M | (m) | $182.00M | 22.16% | 0.87% | (m) | Reported |
| 2012-09-30 | $3.83B | $18.88B | $149.00M | (m) | (m) | 20.28% | 0.79% | (m) | (m) |
| 2012-06-30 | $3.85B | $20.49B | $162.00M | (m) | (m) | 18.80% | 0.79% | (m) | (m) |
| 2012-03-31 | $3.81B | $21.48B | $165.00M | (m) | (m) | 17.75% | 0.77% | (m) | (m) |
| 2011-12-31 | $3.84B | $21.24B | $161.00M | (m) | $145.00M | 18.07% | 0.76% | (m) | Reported |
| 2011-09-30 | $3.84B | $20.90B | $170.00M | (m) | $145.00M | 18.38% | 0.81% | (m) | Reported |
| 2011-06-30 | $3.69B | $20.35B | $178.00M | (m) | $143.00M | 18.14% | 0.87% | (m) | Reported |
| 2011-03-31 | $3.59B | $19.69B | $184.00M | (m) | $143.00M | 18.24% | 0.93% | (m) | Reported |
| 2010-12-31 | $3.57B | $19.48B | $193.00M | (m) | $145.00M | 18.30% | 0.99% | (m) | Reported |
| 2010-09-30 | $3.66B | $19.41B | $196.00M | (m) | (m) | 18.88% | 1.01% | (m) | (m) |
| 2010-06-30 | $3.66B | $19.40B | $191.00M | (m) | (m) | 18.87% | 0.98% | (m) | (m) |
| 2010-03-31 | $3.65B | $19.29B | $187.00M | (m) | (m) | 18.91% | 0.97% | (m) | (m) |
| 2009-12-31 | $3.65B | $18.81B | $183.00M | (m) | (m) | 19.39% | 0.97% | (m) | (m) |
| 2009-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2008-12-31 | $3.51B | $17.71B | $181.00M | (m) | (m) | 19.83% | 1.02% | (m) | (m) |
| 2008-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2008-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2007-12-31 | $3.16B | $15.62B | $133.00M | (m) | (m) | 20.23% | 0.85% | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |